Pediatric multidrug-resistant tuberculosis clinical trials : challenges and opportunities

dc.contributor.authorMcAnaw, S. E.en_ZA
dc.contributor.authorHesseling, A. C.en_ZA
dc.contributor.authorSeddon, J. A.en_ZA
dc.contributor.authorDooley, K. E.en_ZA
dc.contributor.authorGarcia-Prats, A. J.en_ZA
dc.contributor.authorKim, S.en_ZA
dc.contributor.authorJenkins, H. E.en_ZA
dc.contributor.authorSchaaf, H. Simonen_ZA
dc.contributor.authorSterling, T. R.en_ZA
dc.contributor.authorHorsburgh, C. R.en_ZA
dc.date.accessioned2018-09-13T14:06:50Z
dc.date.available2018-09-13T14:06:50Z
dc.date.issued2017
dc.descriptionCITATION: McAnaw, S. E., et al. 2017. Pediatric multidrug-resistant tuberculosis clinical trials : challenges and opportunities. International Journal of Infectious Diseases, 56:194–199, doi:10.1016/j.ijid.2016.11.423.
dc.descriptionThe original publication is available at https://www.ijidonline.com
dc.description.abstractOn June 17, 2016, RESIST-TB, IMPAACT, Vital Strategies, and New Ventures jointly hosted the Pediatric Multidrug Resistant Tuberculosis Clinical Trials Landscape Meeting in Arlington, Virginia, USA. The meeting provided updates on current multidrug-resistant tuberculosis (MDR-TB) trials targeting pediatric populations and adult trials that have included pediatric patients. A series of presentations were given that discussed site capacity needs, community engagement, and additional interventions necessary for clinical trials to improve the treatment of pediatric MDR-TB. This article presents a summary of topics discussed, including the following: current trials ongoing and planned; the global burden of MDR-TB in children; current regimens for MDR-TB treatment in children; pharmacokinetics of second-line anti-tuberculosis medications in children; design, sample size, and statistical considerations for MDR-TB trials in children; selection of study population, design, and treatment arms for a trial of novel pediatric MDR-TB regimens; practical aspects of pediatric MDR-TB treatment trials; and strategies for integrating children into adult tuberculosis trials. These discussions elucidated barriers to pediatric MDR-TB clinical trials and provided insight into necessary next steps for progress in this field. Investigators and funding agencies need to respond to these recommendations so that important studies can be implemented, leading to improved treatment for children with MDR-TB.en_ZA
dc.description.urihttps://www.ijidonline.com/article/S1201-9712(16)31643-5/fulltext
dc.description.versionPublisher's version
dc.format.extent6 pages
dc.identifier.citationMcAnaw, S. E., et al. 2017. Pediatric multidrug-resistant tuberculosis clinical trials : challenges and opportunities. International Journal of Infectious Diseases, 56:194–199, doi:10.1016/j.ijid.2016.11.423
dc.identifier.issn1878-3511 (online)
dc.identifier.issn1201-9712 (print)
dc.identifier.otherdoi:10.1016/j.ijid.2016.11.423
dc.identifier.urihttp://hdl.handle.net/10019.1/104429
dc.language.isoen_ZAen_ZA
dc.publisherElsevier on behalf of International Society for Infectious Diseases
dc.rights.holderAuthors retain copyright
dc.subjectTuberculosisen_ZA
dc.subjectMultidrug-resistant tuberculosisen_ZA
dc.titlePediatric multidrug-resistant tuberculosis clinical trials : challenges and opportunitiesen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
mcanaw_pediatric_2017.pdf
Size:
332.1 KB
Format:
Adobe Portable Document Format
Description:
Download article
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description: